ITGR

Business Context and Reporting Period

Company: Wilson Greatbatch Technologies, Inc. (Note: Input metadata referenced "Integer Holdings Corp," but the filing text identifies the registrant as Wilson Greatbatch Technologies, Inc.)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter ended March 31, 2005 (13 weeks)
Business Overview: The Company operates two segments: Implantable Medical Components (IMC), manufacturing batteries and components for pacemakers and defibrillators, and Electrochem Commercial Power (ECP), producing power sources for oil/gas, oceanographic, and aerospace applications.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Sales increased 2% year-over-year. The IMC segment declined 1% due to lower demand for wet tantalum capacitors and price reductions, while the ECP segment grew 17% driven by pipeline inspection demand.
• Profitability: Net income decreased 40% to $4.0 million. Operating income dropped 40% to $6.3 million.
• Margins: Gross margin contracted by 480 basis points (4.8%) primarily due to excess capacity costs at the Tijuana and capacitor plants, and lower selling prices.
• Expenses: "Other operating expense" surged 981% to $2.4 million, driven by $1.5 million in severance charges from a 4% workforce reduction and costs related to facility consolidations.
• Cash Flow: Operating cash flow decreased slightly. Investing activities consumed $12.6 million, primarily for capital expenditures at the Alden, NY and Tijuana, Mexico facilities.

Guidance, Outlook, and Risks

Management Commentary & Outlook

• Facility Consolidation: The Company is consolidating operations into new facilities in Alden, NY, and Tijuana, Mexico. Estimated total costs for these consolidations range from $8.0 million to $9.4 million, to be incurred over the next three to four quarters.
• Product Development: Focus is on the Q-Series batteries (High Rate and Medium Rate) utilizing nanotechnology to offer smaller size and higher energy density.
• Capital Expenditures: Full-year 2005 capital spending is expected to be between $30.0 million and $35.0 million.
• Tax Rate: Management anticipates the full-year effective tax rate will not exceed 30.0%.

Risks and Contingencies

• Covenant Compliance: As of March 31, 2005, the Company was not in compliance with one financial covenant in its $20.0 million revolving credit agreement. Management is negotiating an amendment expected by May 31, 2005, which may include a larger credit line and revised covenants.
• Litigation:
  • 2002 Case: A former customer alleges misuse of proprietary information. Potential loss is estimated between $0 and $1.75 million; no accrual made.
  • May 2005 Case: A complaint was filed alleging breach of a 2002 supply agreement for drug delivery pumps. Plaintiff seeks significant damages. The Company intends to vigorously defend.
• Accounting Changes: Adoption of SFAS No. 123(R) regarding stock-based compensation is expected on January 1, 2006, which will likely reduce reported net income and EPS.

Investor Verification Checklist

• Credit Agreement Status: Verify the final terms of the amended credit agreement and confirmation of compliance with new covenants.
• Restructuring Costs: Monitor the actual cash outflow and timing of the $8.0M–$9.4M facility consolidation costs against the projected schedule.
• Segment Mix: Track the recovery of the IMC segment, specifically the demand for wet tantalum capacitors versus the growth in ICD batteries and enclosures.
• Litigation Exposure: Review updates on the May 2005 supply agreement lawsuit and the 2002 proprietary information case.
• Capital Allocation: Confirm that capital expenditures remain within the $30M–$35M guidance range and do not strain liquidity.